As of Nov 17
| 0.00 / 0.00%|
The 32 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 50.75, with a high estimate of 62.90 and a low estimate of 32.78. The median estimate represents a -0.31% decrease from the last price of 50.91.
The current consensus among 34 polled investment analysts is to Hold stock in Novo Nordisk. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.